Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PhaseBio Pharmaceuticals, Inc. - Common Stock (NQ: PHAS )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Nov 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PhaseBio Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Trevi Therapeutics (NASDAQ:TRVI) stock rose 45.8% to $2.77 during Thursday's regular session. Trevi Therapeutics's stock is trading at a volume of 15.2... 
Via Benzinga
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Yumanity Therapeutics (NASDAQ:YMTX) shares rose 13.3% to $1.7 during Friday's pre-market session. The market value of their outstanding shares is at $18.4... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers IGM Biosciences (NASDAQ:IGMS) shares rose 114.8% to $32.2 during Tuesday's regular session. IGM Biosciences's stock is trading at a volume of 31.6 million... 
Via Benzinga
Looking Into PhaseBio Pharmaceuticals's Return On Capital Employed
Benzinga Pro data, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported Q4 sales of $158.00 thousand. Earnings fell to a loss of $43.11 million, resulting in a 35.04% decrease from... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
58 Biggest Movers From Yesterday
Gainers Allego N.V. (NYSE: ALLG) shares surged 114.1% to close at $17.73 on Wednesday after the company announced the completion of its merger agreement with Spartan Acquisition... 
Via Benzinga
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 95 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
52 Weeks High And Low Article
On Friday, 106 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Air Products & Chemicals (NYSE:APD) is the largest company... 
Via Benzinga
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The... 
Via Benzinga
PhaseBio Provides Pemziviptadil (PB1046) Program Update
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 109 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company in terms of market cap... 
Via Benzinga
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cumberland (NASDAQ:CPIX) share... 
Via Benzinga
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Rani Therapeutics Hldgs (NASDAQ:RA... 
Via Benzinga
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of... 
Via Benzinga
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The... 
Via Benzinga
PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.